nav-left cat-right
cat-right

Researchers find candidates for new HIV drugs

While studying an HIV protein that plays an essential role in AIDS progression, researchers at the University of Pittsburgh School of Medicine have discovered compounds that show promise as novel treatments for the disease. HIV drug discovery efforts have met with little success in finding compounds that interact with an important HIV virulence factor, called Nef, because it lacks biochemical activity that can be directly...

AIDS Study Flushes Out Hidden Virus, Pointing to P...

Oct. 2 (Bloomberg) — Scientists, moving closer to a cure for AIDS, identified a way to find medicines that would help rid patients of the hardest-to-treat pockets of HIV. Current anti-HIV drugs reduce the virus to undetectable levels without eradicating it. The virus survives by lying dormant in immune-system cells, where the medicines don’t reach them. Scientists from Johns Hopkins University and the Howard...

Sirona Biochem Optimizes Key Test for Diabetes and...

VANCOUVER, BC — (Marketwire) — 07/16/09 — Sirona Biochem Corp. (TSX-V: SBM) announced today it is now ready to begin testing its novel new compounds to fight diabetes and obesity. The completion of the company’s key SGLT biological assessment test and testing will be done under contract with Richmond, BC based SignalChem. Sirona Biochem owns the worldwide rights to a library of potential new sodium...

CytRx Unveils Clinical Development Plan for Pipeli...

Names World-Renowned Cancer Drug Expert Dr. Joseph Rubinfeld as Chief Scientific Advisor LOS ANGELES–(BUSINESS WIRE)–CytRx Corporation (NASDAQ: CYTR) today unveiled its corporate strategy to focus its internal resources on the clinical development of oncology drug candidates tamibarotene and INNO-206, which the Company believes offer the greatest mix of near-term and medium-term...

MorphoSys and Galapagos Enter Alliance to Co-devel...

Combination of Proprietary Drug Targets and Unique Technologies to Create Range of New Therapeutic Antibodies MUNICH, GERMANY — (Marketwire) — 11/26/08 — MorphoSys AG (FSE: MOR; Prime StandardSegment, TecDAX) and Galapagos NV (Euronext: GLPG) announced today the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and...
Page 5 of 512345